BL
TEVA icon

Balentine LLC’s Teva Pharmaceuticals TEVA Stock Holding History

Balentine LLC’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,047
Closed -$88K – 651
2021
Q4 		$88K Buy
+11,047
New +$99.7K ﹤0.01% 368
2020
Q3 		– Sell
-386
Closed -$5K – 772
2020
Q2 		$5K Buy
+386
New +$4.37K ﹤0.01% 744
2019
Q4 		– Sell
-262
Closed -$2K – 748
2019
Q3 		$2K Buy
262
+37
+16% +$283 ﹤0.01% 648
2019
Q2 		$2K Sell
225
-480
-68% -$5.79K ﹤0.01% 651
2019
Q1 		$11K Buy
+705
New +$12.4K ﹤0.01% 259
2018
Q4 		– Sell
-1,761
Closed -$38K – 477
2018
Q3 		$38K Buy
+1,761
New +$40.9K ﹤0.01% 90
2017
Q4 		– Sell
-268
Closed -$5K – 660
2017
Q3 		$5K Buy
268
+2
+0.8% +$45 ﹤0.01% 521
2017
Q2 		$9K Buy
266
+2
+0.8% +$62 ﹤0.01% 453
2017
Q1 		$8K Sell
264
-73
-22% -$2.49K ﹤0.01% 436
2016
Q4 		$12K Buy
337
+77
+30% +$3.07K ﹤0.01% 387
2016
Q3 		$12K Buy
260
+1
+0.4% +$52 ﹤0.01% 339
2016
Q2 		$13K Buy
259
+2
+0.8% +$106 ﹤0.01% 310
2016
Q1 		$14K Buy
257
+1
+0.4% +$59 ﹤0.01% 215
2015
Q4 		$17K Sell
256
-722
-74% -$44.6K ﹤0.01% 267
2015
Q3 		$55K Sell
978
-72
-7% -$4.67K 0.01% 155
2015
Q2 		$62K Buy
1,050
+1
+0.1% +$62 0.01% 132
2015
Q1 		$65K Buy
+1,049
New +$61K 0.01% 117

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Balentine LLC's TEVA Position: Q1 2022 in Review

Balentine LLC sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 11,047 shares — an estimated $88K sold.

Balentine LLC first reported a position in TEVA in Q1 2015 and held it in 17 quarters. The position peaked at $88K in Q4 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Balentine LLC reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Balentine LLC sold 11,047 Teva Pharmaceuticals shares in Q1 2022, an estimated $88K.
  • Balentine LLC first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 17 quarters.
  • Balentine LLC's Teva Pharmaceuticals position peaked at $88K in Q4 2021.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Balentine LLC's 13F filing for Q1 2022, filed 6 May 2022.